Dublin, Aug. 09, 2023 (GLOBE NEWSWIRE) -- The "Global Cell Dissociation Market by Product (Trypsin, Papain, DNase, Hyaluronidase, Instruments), Tissue Type (Connective Tissue, Epithelial Tissue), End-user (Pharma, Biopharma, Research Institutes) & Region - Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.
The global cell dissociation market is on a trajectory of substantial growth, projected to soar from USD 600 million in 2023 to a staggering USD 1.4 billion by 2028, exhibiting an impressive CAGR of 17.8%.
This remarkable surge can be attributed to several key factors, including the rising demand for recombinant therapeutics sourced from mammalian cells and a growing emphasis on personalized medicine. Moreover, the market is bolstered by the increasing approvals for Good Manufacturing Practice (GMP) certification for cell therapy production facilities.
Additionally, advancements in non-enzymatic tissue dissociation techniques are expected to unlock lucrative market opportunities. In-depth insights into the cell dissociation market, segmented by product, tissue type, application, end-user, and region, are thoroughly analyzed in this comprehensive report.
Stakeholders will gain valuable understanding of the market dynamics, including drivers, restraints, opportunities, and challenges, paving the way for informed decisions and strategic planning. The report also sheds light on the competitive landscape, evaluating the position of market leaders and presenting micro-markets' growth trends and prospects.
With a keen focus on four major regions, the forecasted revenue of market segments is meticulously provided, enabling a comprehensive outlook of the global cell dissociation market.
Enzymatic dissociation products segment to witness the highest growth during the forecast period
Based on product, the cell dissociation market is segmented into enzymatic dissociation agents, non-enzymatic dissociation agents, and instruments & accessories.
The enzymatic dissociation agents segment dominated the cell dissociation market in 2022. It is expected to hold the largest share till 2028. The expanding pool of operational entities in this segment and established protocols for using enzymatic dissociation agents are key contributors to market growth.
Non-enzymatic alternatives for cell dissociation are being developed to overcome the limitations of traditional enzymes. Instruments and accessories form a niche segment, with few manufacturers active.
Connective tissue segment to register the highest growth in the cell dissociation market during the forecast period
Based on tissue type, the cell dissociation market has been segmented into connective tissue, epithelial tissue, and other tissues (muscle tissue, lung tissue, and nerve tissue). Connective tissue dominated the cell dissociation market in 2022. The extensive research on connective tissues has ensured a high share of this segment. However, the epithelial tissue segment is expected to grow at the highest rate over the forecast period.
Asia-Pacific is estimated to register the highest CAGR during the forecast period
The Asia-Pacific market is estimated to register the highest growth during the forecast period primarily due to the rising R&D investments in the pharmaceutical sectors of several emerging APAC countries, favorable regulatory guidelines & government support, lower manufacturing costs, and increasing incidence of diseases.
Competitive landscape
The prominent players in the global cell dissociation market are Merck KGaA (Germany), Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Corning Incorporated (US), Becton, Dickinson and Company (US), STEMCELL Technologies (Canada), PromoCell GmbH (Germany), Miltenyi Biotec (Germany), ATCC (US), HiMedia Laboratories (India), and Genlantis, Inc. (US).
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 196 |
| Forecast Period | 2023 - 2028 |
| Estimated Market Value (USD) in 2023 | $0.6 Billion |
| Forecasted Market Value (USD) by 2028 | $1.4 Billion |
| Compound Annual Growth Rate | 17.8% |
| Regions Covered | Global |
Market Dynamics
Drivers
- Increase in Recombinant Therapeutics Sourced from Mammalian Cells
- Growing Focus on Personalized Medicine
- CGMP Approvals for New Cell Therapy Production Facilities
Restraints
- High Cost of Cell-based Research
Opportunities
- Advancements in Non-Enzymatic Tissue Dissociation
Challenges
- Limitations Associated with Dissociated Cell Culture
Company Profiles
Key Players
- Thermo Fisher Scientific
- Merck KGaA
- Cytiva (Danaher Corporation)
- Becton, Dickinson and Company
- Corning Inc.
- Promocell GmbH
- Miltenyi Biotec
- ATCC
- HiMedia Laboratories
- Pan-Biotech
- CellSystems GmbH
- AMSBio
- Neuromics
- Other Players
- Vitacyte
- Alstembio
- Biological Industries (Sartorius)
- Geminibio
- Innovative Cell Technologies, Inc.
- Central Drug House (P) Ltd.
- Worthington Biochemical Corporation
- Capricorn Scientific
- Abeomics
- Genlantis
For more information about this report visit https://www.researchandmarkets.com/r/458o84
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
